Key Developments: ACADIA Pharmaceuticals Inc (ACAD.O)

ACAD.O on Nasdaq

22.30USD
11 Jul 2014
Price Change (% chg)

$0.86 (+4.01%)
Prev Close
$21.44
Open
$21.45
Day's High
$22.43
Day's Low
$21.27
Volume
843,061
Avg. Vol
1,515,283
52-wk High
$32.00
52-wk Low
$15.64

Search Stocks

Latest Key Developments (Source: Significant Developments)

Acadia Pharmaceuticals announces management change - Form 8-K
Friday, 11 Apr 2014 05:08pm EDT 

Acadia Pharmaceuticals Inc:As previously announced, Thomas H. Aasen, executive vice president, chief financial officer and chief business officer of company, informed company that he would be retiring due to health and family-related considerations.On April 9, Aasen informed company that his last day will be April 18.ACADIA has an ongoing search for Aasen's replacement as chief financial officer.In connection with Aasen's retirement, on April 11, Board appointed Uli Hacksell, Ph.D., the company's president and chief executive officer, as principal financial officer and principal accounting officer effective as of Aasen's retirement.  Full Article

ACADIA Pharmaceuticals Inc prices public offering of common stock
Tuesday, 4 Mar 2014 07:28pm EST 

ACADIA Pharmaceuticals Inc:Announced the pricing of an underwritten public offering of 6,400,000 shares of its common stock, offered at a price to the public of $28.50 per share.Says the gross proceeds from this offering to ACADIA are expected to be $182.4 million.ACADIA has granted the underwriters a 30 day option to purchase up to an aggregate of 960,000 shares of common stock.Says the offering is expected to close on or about March. 10, 2014.Says ACADIA expects to use net proceeds of this offering to fund ongoing and new clinical trials and for general corporate purposes.Says Jefferies LLC and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering.Cowen and company, LLC is acting as the lead manager for the offering.Says JMP Securities LLC, Needham & company, LLC, Ladenburg Thalmann & Co., and Roth Capital Partners are acting as co-managers for the offering.  Full Article

Acadia Pharmaceuticals Inc announces proposed public offering of common stock
Monday, 3 Mar 2014 04:01pm EST 

Acadia Pharmaceuticals Inc:Intends to offer and sell, subject to market and other conditions, $150,000,000 of shares of its common stock in an underwritten public offering.Jefferies LLC and J.P. Morgan Securities LLC are acting as the joint book-running managers for the offering.Cowen and Company, LLC is acting as the lead manager for the offering.  Full Article

Acadia Pharmaceuticals Inc announces retirement of CFO - Form 8-K
Monday, 13 Jan 2014 04:08pm EST 

Acadia Pharmaceuticals Inc:Says on Jan 10, Thomas H. Aasen, Executive Vice President, Chief Financial Officer and Chief Business Officer of ACADIA Pharmaceuticals Inc. informed the company that, following a transition period, he would be retiring due to health and family-related considerations.  Full Article

Acadia Pharmaceuticals Inc Announces Initiation Of Phase II Trial With Pimavanserin For Alzheimer's Disease Psychosis
Thursday, 14 Nov 2013 09:00am EST 

ACADIA Pharmaceuticals Inc announced that it has initiated a Phase II feasibility trial designed to examine the efficacy and safety of pimavanserin as a treatment for patients with Alzheimer`s disease psychosis (ADP). No drug is approved in the United States to treat ADP and the off-label use of current antipsychotics is linked to increased mortality, serious adverse events, and cognitive decline in elderly patients with dementia-related psychosis. The Phase II feasibility trial, referred to as the -019 Study, is a randomized, double-blind, placebo-controlled study designed to examine the efficacy and safety of pimavanserin in about 200 patients with ADP. The study is being conducted through a network of research care homes established as part of the National Institute for Health Research (NIHR) Maudsley Biomedical Research Unit. Following a screening period that includes brief psycho-social therapy, patients will be randomized on a one-to-one basis to receive either 40 mg of pimavanserin or placebo once-daily for 12 weeks. The -019 Study will assess several key efficacy endpoints, including use of the Neuropsychiatric Inventory - Nursing Home (NPI-NH) scale to measure psychosis (hallucinations and delusions), agitation/aggression, and sleep/nighttime behavior, as well as use of the Cohen-Mansfield Agitation Inventory - Short Form (CMAI-SF) scale and the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change (ADCS-CGIC) scale.  Full Article

Acadia Pharmaceuticals Inc Prices Public Offering Of Common Stock
Wednesday, 15 May 2013 08:00am EDT 

Acadia Pharmaceuticals Inc announced the pricing of an underwritten public offering of 8,000,000 shares of its common stock, offered at a price to the public of $12.50 per share. The gross proceeds from this offering to ACADIA are expected to be $100 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by ACADIA. ACADIA has granted the underwriters a 30-day option to purchase up to an aggregate of 1,200,000 shares of common stock to cover over-allotments, if any. The offering is expected to close on or about May 20, 2013, subject to customary closing conditions. ACADIA expects to use net proceeds of this offering to fund ongoing and new clinical trials and development and commercialization efforts for pimavanserin and its other product candidates and for general corporate purposes, which may include research, development and commercialization expenses, capital expenditures, working capital, and general and administrative expenses. Jefferies LLC and Cowen and Company, LLC are acting as the joint book-running managers for the offering. JMP Securities LLC, Needham & Company, LLC, Ladenburg Thalmann & Co. Inc., Roth Capital Partners, LLC, and SunTrust Robinson Humphrey, Inc. are acting as co-managers for the offering.  Full Article

Acadia Pharmaceuticals Inc Announces Proposed Public Offering of Common Stock
Tuesday, 14 May 2013 04:01pm EDT 

Acadia Pharmaceuticals Inc announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Jefferies LLC and Cowen and Company, LLC are acting as the joint book-running managers for the offering. JMP Securities LLC and Needham & Company, LLC are acting as co-managers for the offering.  Full Article

Faruqi & Faruqi, LLP Launches Investigation Against Acadia Pharmaceuticals Inc For Potential Breaches Of Fiduciary Duties By Board Of Directors
Friday, 10 May 2013 06:45pm EDT 

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a national securities firm headquartered in New York City, is investigating the Board of Directors of ACADIA Pharmaceuticals Inc. for potential breaches of fiduciary duties in connection with their conduct in seeking shareholders' approval for an amendment to the Company's 2010 Equity Incentive Plan. Specifically, in the Proxy Statement filed by the Company with the Securities and Exchange Commission on April 25, 2013, the Board of Directors recommends that ACADIA's shareholders vote to approve an amendment to the Company's 2010 Equity Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance under the plan by 7,500,000 shares. The issuance of the additional shares could have a substantial dilutive effect on the shares of ACADIA common stock.  Full Article

Acadia Pharmaceuticals Inc Announces Expedited Path To NDA Filing For Pimavanserin Following Meeting With FDA
Thursday, 11 Apr 2013 07:00am EDT 

Acadia Pharmaceuticals Inc announced that the U.S. Food and Drug Administration (FDA) has agreed that the data from the pivotal Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application (NDA) for the treatment of Parkinson's disease psychosis (PDP). As a result, ACADIA will no longer conduct the Phase III -021 study that was planned as a confirmatory trial and was scheduled to be initiated later this month. ACADIA is currently focused on completing the remaining elements of pimavanserin PDP development program that are needed for submission of an NDA. These include customary supportive studies, such as drug-drug interaction studies, and CMC development, such as stability testing of registration batches. Subject to changes that could result from future interactions with the FDA or other developments, ACADIA is currently targeting an NDA submission near the end of 2014.  Full Article

Acadia Pharmaceuticals Inc Announces Presentation of Data from Its Pivotal Phase III Parkinson’s Disease Psychosis Study with Pimavanserin at the American Academy of Neurology Annual Meeting
Wednesday, 20 Mar 2013 10:00pm EDT 

Acadia Pharmaceuticals Inc announced detailed results from its pivotal Phase III -020 Study with pimavanserin in patients with Parkinson`s disease psychosis at the Emerging Science session of the 65th American Academy of Neurology (AAN) Annual Meeting. The analysis of the full data set from the Phase III -020 Study showed robust and consistent efficacy of pimavanserin across a wide array of study measures and confirmed the positive top-line results previously reported. Pimavanserin met the primary endpoint in the -020 Study by demonstrating highly significant antipsychotic efficacy on the 9-item SAPS-PD scale (p=0.001). Pimavanserin also met the key secondary endpoint for motoric tolerability as measured using Parts II and III of the Unified Parkinson`s Disease Rating Scale, or UPDRS. Dr. Cummings presented new data from the -020 Study showing highly significant improvements in all secondary efficacy measures, including the Clinical Global Impression Severity, or CGI-S, scale (p <0.001), the Clinical Global Impression Improvement, or CGI-I, scale (p=0.001), and a CGI-I responder analyses (p=0.002). The CGI-I responder results showed that approximately twice as many subjects in the pimavanserin treatment arm, as compared to placebo, were rated as very much improved or much improved at the conclusion of the study.  Full Article

Search Stocks